Table 5 Characteristics of patients who developed hepatotoxicity
Case | Age Gender | Reaction day | Skin sign | First treatment | Hypersensitivity developing treatment | Desensitization applied regime | Responsible agent |
|---|---|---|---|---|---|---|---|
1 | 40, F | 0 | Pruritus | HRZE | Isoniazide Ethambutol Moxifloxacin Cyloserine Amikasin | Isoniazide Etambutol Moxifloxacin Cyloserine AmIkasIn | |
2 | 73, M | 1 | Urticaria | Etambutol Moxifloxacin Cyloserine Streptomycin | Etambutol Moxifloxacin Cyloserine Streptomycin | ||
3 | 18, M | 1 | Pruritus | Isoniazide Rifampicine Etambutol Moxifloxacin | Isoniazide Rifampicine Etambutol Moxifloxacin | ||
4 | 41, F | 0 | Pruritus | Isoniazide Etambutol Pyazinamide Moxifloxacin Cyloserine | Isoniazide Etambutol Pyazinamide Moxifloxacin Cyloserine | ||
5 | 63, M | 2 | Pruritus | Isoniazide Etambutol Pyazinamide Cyloserine Protionamid PAS | Isoniazide Etambutol Moxifloxacin Linezolid | PAS Protionamid | |
6 | 37, M | 1 | Pruritus | Isoniazide Rifampicine Etambutol Moxifloxacin | Isoniazide Rifampicine Etambutol Moxifloxacin | ||
7 | 56, M | 1 | Pruritus | Isoniazide Rifampicine Moxifloxacin | Isoniazide Rifampicine Moxifloxacin |